Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients?

Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer

LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients

KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma